Glaxo signage touts firm's drug-testing role in '12 Games

Share this article:
Glaxo signage touts firm's drug-testing role in '12 Games
Glaxo signage touts firm's drug-testing role in '12 Games

GlaxoSmithKline got help from British olympian Rebecca Romero in unfurling new signage at its London headquarters today.

Featuring the jagged “2012” logos for the upcoming Olympic and Paralympic Games in London along with the slogan “Bringing Science to the Games,” the sign plays up Glaxo's commitment to keeping the events drug free.

“Millions of people will see it in the lead up to the Games and during Games time itself,” said Glaxo CEO Andrew Witty.

Witty said the firm had wanted to celebrate its role as official lab services provider for the summer spectacle, during which the company will go for its own record.

GSK and King's College London will operate a World Anti-Doping Agency (WADA) accredited lab. Over the course of the event, the lab will oversee 6,250 drug tests—the most ever at an Olympic and Paralympic Games, Glaxo said.

Romero, who won a gold medal for England as a cyclist in the 2008 Beijing Summer Games after taking silver at the 2004 Games in Athens as a rower, was on-hand for the debut.

Sitting on the side of GSK's building next to two highways, the sign can be seen by people traveling into the capital from Heathrow and the West of England.

Hugh Robertson, UK minister for sport and the olympics, called GSK's drug-testing work “vital in enhancing the UK's reputation as a nation that is robust and effective in tackling drug cheats and sends out the clear message that doping in sport is something we simply will not tolerate."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...